Monday, May 03, 2021
BioVaxys Technology Corp., the world's leading provider of haptenized antigen vaccines for antiviral and cancer applications, announced today that it is at US Patent and Trademark Office ("USPTO") has filed an application of intent to register the trademark CoviDTH®, a novel, single-use test of T-cell immune response to SARS-CoV-2.
Kenneth Kovan , President and CEO of BioVaxys , stated, “We are close to launch and we need to register a trademark that is descriptive, memorable and defensible. CoviDTH® is an ideal brand name as it combines the letters DTH (Delayed Hypersensitivity), the mechanism behind our diagnosis of the T-cell immune response, with Covid-19. "
In a further step in expanding its patent portfolio, BioVaxys expanded patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application under the Patent Collaboration Agreement ("PCT") with additional claims for cervical cancer BioVaxys are in line with the company's development plans for oncology vaccines and include cervical and ovarian cancer, other gynecological cancers such as uterine, vaginal, vulvar and endometrial cancer, as well as melanoma, lung cancer and renal cell carcinoma , Pancreatic cancer, colon cancer, breast cancer and leukemia.
An international PCT application under the Treaty on International Cooperation in the Field of Patents (PCT) with more than 150 members makes it possible to apply for patent protection for an invention in a large number of countries at the same time by filing a single "international" patent application instead of several In March 2021, BioVaxys started the national phase with its patent application for the bihaptenized tumor antigen platform in order to obtain extended patent protection in the most important pharmaceutical markets, including the USA , the European Union (including Great Britain and Turkey), Australia , Canada, China , India, Japan , Russia, Brazil and South Korea.
BioVaxys 'pursuit of a patent claim for cervical cancer vaccines is related to its partnership with Procare Health Iberia in Barcelona , Spain, to jointly develop BioVaxys' bihaptenized antigen vaccine platform for ovarian cancer, cervical cancer and human papillomavirus ("HPV") includes, as well as the right of first refusal to commercialize Procare Health's Papilocare ™ vaginal gel, the world's first and only product for the prevention and treatment of HPV-related cervical lesions, by BioVaxys in the United States.
About BioVaxys Technology Corp.
In Vancouver resident BioVaxys Technology Corp . is a in British Columbia Registered early stage biotechnology company developing viral and oncological vaccine platforms and immunodiagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and plans to conduct a clinical trial of its haptenized autologous cell vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors to be developed for ovarian cancer. A diagnostic test to assess the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19, is also under development. BioVaxys has two issued U.S. patents and two patent applications related to its cancer vaccine and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys' common stock is listed on the CSE under the symbol "BIOV" and is listed on the Frankfurt Stock Exchange (FRA: 5LB) and US OTC: BVAXF.
Cautionary Statements Regarding Forward-Looking Information
This press release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of theapplicable Canadian and US securities laws including the United States Private Securities Litigation Reform Act of 1995. All statements contained herein that are not historical facts, including but not limited to statements about the company's future operating or financial performance, are forward-looking statements. Forward-looking statements are often, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potentially," "possible" and similar expressions, or statements that will occur , Conditions or results "will", "may", "could" or "should".There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections at the time the statements were made and are based on a number of assumptions and estimates, most notably the belief that BioVaxys will be successful in developing and testing vaccines will be. While Company believes these assumptions and estimates are reasonable, they are inherently subject to significant business, economic, competitive, political and social uncertainties and uncertainties, including the risk that BioVaxys' vaccines may not prove effective and / or not provide the necessary vaccines Obtain regulatory approvals. There are a number of risks associated with BioVaxys' business,
The company assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors if they change unless required by law.
Signiert, James Passin
James Passin, CEO
+1 646 452 7054
Pressekontakte BioVaxys Technology Corp.: